Best in Biotech 25 Feb 2025 Seven biotech spinouts to watch out for in 2025 Here are seven biotech spinouts to keep an eye out for this year that specialize in a number of therapeutic areas. February 25, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues. February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 18 Feb 2025 T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments T cell engagers represent a novel approach to tuning the immune system to target and kill tumor cells, expanding treatment options for cancer. February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 14 Feb 2025Reversing cancer mechanisms to fight back against solid tumors This week, we have a conversation with Catalym’s Eugen Leo about Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15. February 14, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 4 Feb 2025 World Cancer Day: trends in cancer therapeutics to look forward to in 2025 As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer care in 2025. February 4, 2025 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2025 Akribion Therapeutics emerges from stealth with programmable cell depletion RNA technology Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach February 4, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 31 Jan 2025Can tumor activated therapy kill solid tumors? Solid tumors are a big challenge. However, a new approach might provide the answer – tumor-activated Therapy. We discuss this with Seekyo Therapeutics’ CEO, Oury Chetboun January 31, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 29 Jan 2025 Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the clinic Discover the treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to treat. January 29, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2025 ITM-11 succeeds in phase 3: The first big win for radiopharma? Discover ITM and its cancer candidate ITM-11, as it brings one of the first big wins the radiopharmaceutical sector awaits. January 28, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 23 Jan 2025 mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeutics In this review of RNA therapies, we paint an overview of what’s going on in a field that could address a number of diseases. January 23, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2025 Ten first-in-class drugs on track for FDA approval in 2025 As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval in 2025. January 16, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email